IRIDEX Co. (NASDAQ:IRIX – Get Free Report) was the target of a large decline in short interest in October. As of October 31st, there was short interest totalling 309,800 shares, a decline of 8.0% from the October 15th total of 336,800 shares. Based on an average daily volume of 25,000 shares, the days-to-cover ratio is currently 12.4 days. Approximately 2.5% of the company’s stock are short sold.
IRIDEX Stock Up 4.1 %
NASDAQ:IRIX traded up $0.07 during trading hours on Monday, hitting $1.76. 46,351 shares of the company traded hands, compared to its average volume of 31,530. The company has a quick ratio of 0.86, a current ratio of 1.54 and a debt-to-equity ratio of 0.55. The company has a market cap of $29.28 million, a PE ratio of -2.63 and a beta of 0.80. The firm’s 50-day simple moving average is $1.67 and its 200-day simple moving average is $2.01. IRIDEX has a one year low of $1.27 and a one year high of $3.65.
IRIDEX (NASDAQ:IRIX – Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share for the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The firm had revenue of $11.58 million for the quarter. During the same quarter in the prior year, the firm earned ($0.11) earnings per share.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on IRIDEX
IRIDEX Company Profile
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Further Reading
- Five stocks we like better than IRIDEX
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- The Risks of Owning Bonds
- Applied Materials Market Capitulates: Now is the Time to Buy
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.
